Oncology

Latest News

December 23rd 2024

Prior authorization, PBM reform, and payment for patient navigation were topics of the most popular articles in EBO in 2024.

ICYMI: Highlights From ASCO 2024

By Pearl Steinzor

December 21st 2024

chemotherapy | Image credit: Penn Medicine

The High Cost of Shortages of Low-Cost Chemotherapy

By Interview by Mary Caffrey

December 19th 2024

Leukemia diagnosis | Image credit: Vitalii Vodolazskyi - stock.adobe.com

Real-World Treatment Sequences and Cost Analysis of cBTKis in CLL

By Pearl Steinzor

December 17th 2024

FDA approved stamp in black with a red ribbon across it | Image credit: BHM - stock.adobe.com

Cosibelimab Approved for Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

By Kristi Rosa

December 16th 2024

Join this panel as they discuss treatment for metastatic NSCLC patients without driver mutations.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

October 20th 2014

A SNP That Affords Protection From Breast Cancer Identified

The study, published in the journal Nature Communications, identified the single nucleotide polymorphism near the coding region of the estrogen receptor ESR1 among Latina women.

October 20th 2014

Including Panobinostat Improves PFS in Multiple Myeloma

Including panobinostat in a regimen that included bortezomib and dexamethasone improved median PFS to 11.9 months as compared with 8.08 months in the control arm.

October 19th 2014

Success of Medicare's Prescription-Subsidy Program Among Low-Income Women

A study presented at ASCO's Quality Care Symposium in Boston found increased medication adherence to prevent breast cancer recurrence in those availing of the subsidies.

October 18th 2014

CMS Issues Draft Coverage Decision For Prostate Cancer Test by GenomeDX

The Decipher test is intended for use in men who have undergone radical prostatectomy and are at a high risk of disease recurrence.

October 18th 2014

Janssen's Imbruvica Approved by the European Commission

Imbruvica (ibrutinib) is a first-in-class BTK inhibitor with potential for treating blood cancer, indicated for use in MCL and CLL patients.

October 18th 2014

Exact Sciences' Cologuard Receives CMS National Coverage

The non-invasive nature of the test makes it a very attractive alternative to the uncomfortable colonoscopy used to detect colorectal cancer. In a New England Journal of Medicine study of 10,000 patients, the test identified 92% of colorectal cancers in average-risk patients and 42% of polyps.

October 17th 2014

Roche Joins the Immuno-oncology Front With a PD-L1 inhibitor

While the current approved immuno-oncolgy drugs have been approved for melanoma, Roche has also been evaluating their new molecule in triple-negative breast cancer. The results will be presented at the San Antonio Breast Cancer Symposium.

October 16th 2014

Exciting Clinical Results With Novartis' Leukemia Immune Therapy

The regimen, based on reprogramming the patient's immune T cells to attack the cancer cells, led to the disappearance of cancer in 90 percent of patients, according to a study published in the New England Journal of Medicine.

October 15th 2014

After Roche, Celgene Faces Value Push-Back From NICE

After Roche saw 2 product rejects a few weeks back from NICE, based on a value argument, Celgene is in a similar boat with it's multiple myeloma drug pomalidomide.

October 14th 2014

Study Identifies Gender Bias in HPV Vaccination

Fewer than 15% of physicians routinely recommend HPV vaccination to male patients, according to the study published in the journal Cancer Epidemiology, Biomarkers & Prevention.

October 14th 2014

ASCO Endorses CAP/IASLC/AMP Guideline on Molecular Testing for Lung Cancer

The American Society of Clinical Oncology has endorsed the joint guidelines established by the 3 Associations to help physicians make evidence-based decisions when selecting patients to administer some of the targeted therapies developed for lung cancer.

October 13th 2014

Transition to Managed Care Proves Rough for Ohio Dual Eligibles, Reports Say

Mary K. Caffrey

Ohio is the latest state to experience a rough transition to managed care in its Medicaid program, according to weekend reports. Delayed payments and service disruptions to fragile patients are among the complaints. Kentucky had a similar bumpy start when it changed to Medicaid managed care in 2011, and Kansas has had many problems recently.

October 13th 2014

BMS' PD-1 Inhibitor, Nivolumab, to be Evaluated With Jansenn's Ibrutinib in NHL

Opdivo (nivolumab), which was approved in Japan in July 2014, is being globally developed for evaluation in non-small cell lung cancer (NSCLC), melanoma, renal cell carcinoma (RCC), head and neck cancer, glioblastoma, as well as NHL.

October 13th 2014

Priority Review for Pfizer's Palbociclib in Patients with Advanced Breast Cancer

The NDA submitted by Pfizer requests approval of palbociclib as a first-line therapy in combination with letrozole for ER+, HER2- advanced breast cancer.

October 11th 2014

Immuno-oncology Innovation From Amgen Set for Priority Review

The new BiTE antibody technology developed by the company can simultaneously engage 2 different targets, which can help recruit T-cells to malignant cells, and will be evaluated in ALL patients.

October 11th 2014

FDA Approves Akynzeo for Chemotherapy-Associated Nausea and Vomiting

The approval follows 2 clinical trials evaluating the regimen in 1720 cancer patients receiving chemotherapy.

October 10th 2014

Velcade Approved For Treatment-NaÃ¯ve Mantle Cell Lymphoma Patients

The approval extends the use of bortezomib beyond relapsed and refractory patients.

October 9th 2014

Urine Test Could Diagnose Prostate Cancer

The identification of specific RNA molecules in the urine of individuals with prostate cancer raises hope for a non-invasive test for the disease.

October 8th 2014

Genentech Faces Backlash Following Onco-Specialty Decision

Having decided to restrict the distribution of 3 of its top-selling oncology medications, Avastin, Rituxan, and Herceptin only through specialty pharmacies, Genentech is witnessing protests in various forms from healthcare centers.

October 8th 2014

Episode 17 - Final Thoughts on the State of Medical Oncology

October 8th 2014

Episode 16 - Impact of Electronic Medical Records in Oncology Practices

October 8th 2014

Episode 15 - Quality Metrics and Patient-Reported Outcomes

October 8th 2014

Episode 14 - Quality Initiatives in Medical Oncology

October 8th 2014

Episode 13 - Patient-Centered Approach to Improve Quality

October 8th 2014

Episode 12 - Cost Considerations and Comparative Effectiveness Research

October 8th 2014

Episode 11 - The Importance of Patient Education

October 8th 2014

Episode 10 - Comparative Effectiveness Research

October 8th 2014

Episode 9 - Analyzing Incentive Programs

October 8th 2014

Episode 8 - Immunotherapy and Pathways: Safety Considerations

October 8th 2014

Episode 7 - Inclusion of Generic Drugs in Pathways

...

145 146 147 148 149 150 151 152 153

...

181 >